Beth Israel Deaconess Medical Center, Inc.

Yvonne Tay

Pier Paolo Pandolfi

Leonardo Salmena

Laura Poliseno

Assaf C Bester

The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).

Micro-RNA inhibitors and their uses in disease

Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.

Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer

The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).

Growing community of inventors

Brookline, MA, United States of America

Yvonne Tay